Variations in the monitoring and management of the side effects of antirheumatic drugs by means of laboratory tests

Clinical and Experimental Rheumatology

Volumn 15, Issue 6, 1997, Pages 633-639

  Simon, C H ^a,b   Dijkmans, B A C ^a,b   Breedveld, F C ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Rheumatology ^*  (Netherlands)

Author keywords

Antirheumatic drags; Monitoring; Side effects

Indexed keywords

AMINOTRANSFERASE; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CREATININE; GOLD; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ARTICLE; DRUG MONITORING; ENZYME ACTIVITY; GENETIC VARIABILITY; HUMAN; LABORATORY TEST; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; PROTEINURIA; RHEUMATIC DISEASE; THROMBOCYTE COUNT; TREATMENT PLANNING; URINALYSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; DRUG MONITORING; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; PHYSICIAN'S PRACTICE PATTERNS; RHEUMATOLOGY;

EID: 0030727681     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. SINGH G, FRIES JF, WILLIAMS CA, ZATARAIN E, SPITZ P, BLOCH DA: Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991; 18: 188-94.
2. FRIES JF, WILLIAMS CA, RAMEY D, BLOCH DA: The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 1993; 36: 297-306.
3. CLEMENTS PJ, PAULUS HE: Nonsteroidal anti-inflammatory drugs (NSAIDs). In KELLY WN, HARRIS ED, RUDDY S, SLEDGE CB (Eds.): Textbook of Rheumatology. Philadelphia, W.B. Saunders Company 1993: 700-30.
4. DAY RO: Sulfasalazine. In KELLY WN, HARRIS ED, RUDDY S, SLEDGE CB (Eds.): Textbook of Rheumatology. Philadelphia, W.B. Saunders Company 1993: 692-9.
5. JAFFE IA: Penicillamine. In KELLY WN, HARRIS ED, RUDDY S, SLEDGE CB (Eds.): Textbook of Rheumatology. Philadelphia, W.B. Saunders Company 1993: 760-6.
6. GORDON DA: Gold compounds in the rheumatic diseases. In KELLY WN, HARRIS ED, RUDDY S, SLEDGE CB (Eds.): Textbook of Rheumatology. Philadelphia, W.B. Saunders Company 1993: 743-59.
7. RYNES RI: Antimalarial drugs. In KELLY WN, HARRIS ED, RUDDY S, SLEDGE CB (Eds.): Textbook of Rheumatology. Philadelphia, W.B. Saunders Company 1993: 731-42.
8. WEINBLATT ME: Methotrexate. In KELLY WN, HARRIS ED, RUDDY S, SLEDGE CB (Eds.): Textbook of Rheumatology. Philadelphia, W.B. Saunders Company 1993: 767-78.
9. FAUCI AS, RANDALL YOUNG K: Immunoregulatory agents. In KELLY WN, HARRIS ED, RUDDY S, SLEDGE CB (Eds.): Textbook of Rheumatology. Philadelphia, W.B. Saunders Company 1993: 797-821.
10. CLEGG DO: Sulfasalazine. In MCCARTY DJ, KOOPMAN WJ (Eds.): Arthritis and Allied Conditions. Malvern, Lea & Febiger 1993: 637-43.
11. RUNGE LA: Antimalarials. In MCCARTY DJ, KOOPMAN WJ (Eds.): Arthritis and Allied Conditions. Malvern, Lea & Febiger 1993: 615-9.
12. SKOSEY JL: Gold compounds and D-penicillamine. In MCCARTY DJ, KOOPMAN WJ (Eds.): Arthritis and Allied Conditions. Malvern, Lea & Febiger 1993: 603-14.
13. ROONEY TW, FURST DE: Methotrexate. In MCCARTY DJ, KOOPMAN WJ (Eds.): Arthritis and Allied Conditions. Malvern, Lea & Febiger 1993: 621-36.
14. CANNON GW, WARD JR: Cytotoxic drugs and combination drug therapy. In MCCARTY DJ, KOOPMAN WJ (Eds.): Arthritis and Allied Conditions. Malvern, Lea & Febiger 1993: 645-63.
15. FURST DE, PAULUS HE: Aspirin and other nonsteroidal antiinflammatory drugs. In MCCARTY DJ, KOOPMAN WJ (Eds.): Arthritis and Allied Conditions. Malvern, Lea & Febiger 1993: 567-602.
16. FURST DE, CLEMENTS PJ: SAARDs-II. In KLIPPEL JH, DIEPPE PA (Eds.): Rheumatology. London, Mosby Year Book Europe Ltd., 1994: 13.1-13.8.
17. BROOKS PM: NSAIDs. In KLIPPEL JH, DIEPPE PA (Eds.): Rheumatology. London, Mosby Year Book Europe Ltd., 1994: 10.1-10.6.
18. DAY RO: SAARDs-I. In KLIPPEL JH, DIEPPE PA (Eds.): Rheumatology. London, Mosby Year Book Europe Ltd., 1994: 12.1-12.10.
19. KAY A: Monitoring of slow-acting remission-inducing (SARI) drugs. Br J Rheumatol 1989; 28: 239-41.
20. KREMER JM, ALARCON GS, LIGHTFOOT RW JR et al.: Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994; 37: 316-28.
21. AD HOC COMMITTEE ON CLINICAL GUIDELINES OF THE ACR: Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39: 723-731.
22. KAY EA, PULLAR T: Variations among rheumatologists in prescribing and monitoring of disease modifying antirheumatoid drugs. Br J Rheumatol 1992; 31: 477-83.
23. COMER M, SCOTT DL, DOYLE DV, HUSKISSON EC, HOPKINS A: Are slow-acting anti-rheumatic drugs monitored too often? An audit of current clinical practice. Br J Rheumatol 1995; 34: 966-70.
24. PRASHKER MJ, MEENAN RF: The total costs of drug therapy for rheumatoid arthritis. A model based on costs of drug, monitoring, and toxicity. Arthritis Rheum 1995; 38: 318-325.
25. AMOS RS, PULLAR T, BAX DE, SITUNAYAKE D, CAPELL HA, MCCONKEY B: Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. Br Med J (Clin Res Ed) 1986; 293: 420-3.
26. LIANG MH, FRIES JF: Containing costs in chronic disease: monitoring strategies in the gold therapy of rheumatoid arthritis. J Rheumatol 1978; 5: 241-4.
27. HARRIS BK, ENGLAND DW, ROSS HA, ROTH SH: Costs of monitoring chrysotherapy. Ariz Med 1977; 31: 250-1.
28. SOMERVILLE W, CAUGHEY DE, GRIGOR RR: Surveillance costs of gold and penicillamine [letter]. NZ Med J 1979; 89: 186.